1 Drugs against HCV infection are facing several drawbacks such as undesirable side effects, 2 emerging of HCV resistant strains, and high cost of the entire course of treatment. Thus, 3 new active and cost-effective compounds are required to develop effective drugs to combat 4 HCV infection. This study was designed to test the antiviral activity of quinazoline derivatives 5 against HCV infection using HCV protease assay (HCV NS3-4Apro) and cell-based HCV 6 replicon assay. The results showed that some of quinazoline derivatives inhibited HCV NS3-7 4Apro with IC 50 ranged from 42 µM of compound 4 to 150 µM of compound 2. In this study, 8 compound 4 was considered as the best compound lead to developing potent anti-HCV 9 NS3-4Apro inhibitors. The toxic dose of compound 4 was more than 80 µM for 24, 48, and 10 72 h. Compound 4 showed dose-dependent inhibition against HCV replication with a 11 considerable reduction in Rluc activity at 40 µM. This finding was further investigated by 12 immunostaining that showed the inhibitory effect of compound 4 against HCV NS3-4Apro 13 was dose-dependent. This study identified a unique small molecule compound that could 14 lead to the development of HCV NS3-A4pro inhibitors and would be useful to develop highly 15 effective drugs for HCV infection based on HCV NS3-4A protease inhibition. 16 17 18 Keywords: Antiviral compounds, Quinazoline derivatives, Hepatitis C virus, NS3-4A serine 19 protease, HCV replicon assay. 20 21 22 23 24 25 26 the inhibitory potential of five unique quinazoline derivatives towards HCV NS3-4A serine 1 protease and their ability to inhibit HCV replication in a cell-based HCV replicon system. 2 Methods 3 Chemical synthesis 4 Compound synthesis and characterization were carried out as previously described (17]. In 5 brief, one equivalent of amino benzhydrazide (2.5 mmol) was dissolved in 50 ml of ethanol. 6 Two equivalent of substituted aromatic salicylaldehyde (5.0 mmol) was then added to this 7 solution in the presence of glacial acetic acid (added as a catalyst at 50-60℃). The reaction 8 mixture was refluxed for 2-3h. The yellow to brown precipitates of the compounds below 9 were formed during the reactions. 10 Expression and Purification of HCV Protease 11 Protein purification was conducted as previously described with modification[18,19]. The 12 long oligonucleotides spanning DNA sequences of HCV genotype 3 proteases (NS3-GSGS-4A 13 pro) were overlapped and extended using Klenow DNA polymerase (Invitrogen, USA). PCR 14 subsequently amplifies the designed full-sized DNA and cloned into E. coli expression vector, 15 PQE30. The recombinant plasmids were then isolated, and the purified plasmids were 16 sequenced to verify the sequence identity of the insert. E. coli harboring the recombinant 17 protease vector was cultured in 1 L of LB medium and expression was induced by addition of 18 1mM IPTG followed by an additional 4 hours incubation at 370C. The bacterial cells were 19 then harvested, lysed, and sonicated on ice. Recombinant protein in the supernatant was 20 purified via Ni2+-NTA (Qiagen, UK) column [20].
Introduction
Hepatitis C virus infection leads to liver inflammation disorders which have been recognized 2 as a global healthcare burden. World Health Organization (WHO) bulletins showed that 3 there are approximately 150 million people is chronically infected with hepatitis C virus 4 (HCV) along with an annual mortality rate of 700, 000 people due to HCV-related liver 5 diseases [1] . Early HCV infections are usually asymptomatic; however, once the infections 6 turned chronic, the patients might face an increased risk of liver-related complications such 7 as liver steatosis, cirrhosis and hepatocellular carcinoma [1, 2] . 8 To date, several direct-acting antiviral agents (DAA) targeting different HCV viral proteins 9 have been approved to treat HCV infection. Some examples include Simeprevir, Daclatasvir, 10 and Sofosbuvir, which targets HCV NS3/4A, NS5A, and NS5B, respectively [3 -6] . Although a 11 myriad of HCV DAA has moved into the market, most of them are facing several drawbacks 12 such as emerging of HCV resistant strains, intolerable side effects, and high pricing issues [7 13 -9]. These issues, therefore, collectively call for the development of new alternatives with 14 better pharmacokinetics and pharmacoeconomic profiles. 15 Quinazoline is bicyclic aromatic heterocycles which consist of a benzene ring fused with a 16 pyrimidine ring [10, 11] . To date, quinazoline moiety has been found in several approved 17 drugs such as Gefitinib, Erlotinib and Prazosin which the first and second both served as an 18 anticancer agent while the latter is used to treat anxiety and hypertension [12] . In addition 19 to the aforementioned pharmaceutical values, quinazoline derivatives also being widely 20 studied for other biological significances, such as anti-inflammatory, anti-tubercular anti- 21 HIV, and anti-serine protease activities [11, 13 -16] . In this study, we have demonstrated NS3-4A HCV protease assay 1 This assay was conducted as previously described with modification [21, 22] . The cleavage of The IC 50 values for each compound were then calculated by fitting data points from each 20 reaction into Graph Prism (version 5.01) dose-response curves. All assays were done in 21 triplicate. 1 Compound 4 (3-(5-methoxy-2-hydroxybenzylideneamino)-2(5-methoxy-2-hydroxyphenyl)- 2 2,3-dihydroquinazoline-4(1H)-one), the most potent inhibitor in this study was modeled by 3 Discovery Studio Client v4.5.0.15071 and minimized by CHARMm force field (Accelrys Inc., 4 Dassault Systèmes, BIOVIA Corp., San Diego, CA, USA) with reference to NCBI PubChem 5 Chemical Structure Search database (https://pubchem.ncbi.nlm.nih.gov/search/search.cgi). 6 The HCV receptor was modeled from HCV genotype3 in-house amino acids sequence by 7 YASARA Structure software, and the minimized ligands were targeted individually on the 8 HCV serine protease catalytic triad at HIS-72, ASP-96, and SER-154 as reported previously. 16 This assay was conducted as previously described [23, 24] . Huh-7 cell lines were seeded at 1 17 × 104 cells per well in triplicate at optimal conditions (37°C, 5% CO2 in a humidified 18 incubator) in 96 well plates. The test compound was diluted to serial concentrations 0, 5, 10, 19 20, 40, and 80 μM with DMEM media supplemented with 2% FBS. Viability of the cell culture 20 was analyzed at 24, 48, and 72 h using nonradioactive cell proliferation assay (Promega, 21 USA) according to the manufacturer's protocol. 18 Quinazoline derivatives were prepared by dissolving amino benzhydrazide in ethanol. Then, 19 the substituted aromatic salicylaldehyde was added to th 20
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Molecular modeling of the ligand and HCV NS3-4Apro
Maximum Nontoxic Dose Test (MNDT)
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HCV-replicon cell-based assay
Inhibition of HCV protease by Quinazoline derivatives
Enzyme Assay with Fluorogenic Peptide Substrate
Recombinant HCV serine protease (NS3-4Apro) was purified by a single-step metal chelate affinity columns to 90% purity ( Fig. 1A) -Met-Glu-Glu-Cys-Ala-Ser-His-Leu-Pro-Tyr-Lys 4Apro, and therefore, it was used in this study as the substrate of assay ( Fig. 1B ). 
: Expression of recombinant HCV NS3-4A protease in E. coli and test the activity
Inhibition of HCV protease by Quinazoline derivatives
Quinazoline derivatives were prepared by dissolving amino benzhydrazide in ethanol. Then, the substituted aromatic salicylaldehyde was added to this solution in the presence of 8 step ( Fig. 1A) . The
Lys was efficiently in this study as the substrate of HCV NS3-4A protease in E. coli and test the activity 4A protease was purified before IPTG induction; L2: After through after first wash; L6: Enzyme activity with increased Ser-His-Leu-Pro-Quinazoline derivatives were prepared by dissolving amino benzhydrazide in ethanol. Then, is solution in the presence of glacial acetic acid at 50-60℃. The reaction mixture was refluxed for 2 1 brown precipitates of the compounds below were formed during the reactions as described . Compounds synthesis of quinazoline compounds. One equivalent benzhydrazide (2.5 mmol) was dissolved in 50 ml of ethanol. Two equivalent of substituted aromatic salicylaldehyde (5.0 mmol) was added to this solution in the presence of glacial acetic acid which was added as a catalyst at 50-60℃. The reaction mixture was refluxed for 3h. The yellow to brown precipitates of the compounds below were formed during the 10 One equivalent of amino benzhydrazide (2.5 mmol) was dissolved in 50 ml of ethanol. Two equivalent of substituted aromatic salicylaldehyde (5.0 mmol) was added to this solution in the presence of glacial mixture was refluxed for 3h. The yellow to brown precipitates of the compounds below were formed during the 
HCV activity of compound 4 using HCV replicon assay
The results of our study have shown that compound 4 considerably inhibit HCV protease in comparison with the rest of the test compounds. Therefore, further analysis was carried out to test the inhibition potential of this compound in a cell-based system using HCV replicon 12 Discovery Studio Client modeled d with reference to NCBI PubChem Chemical Structure Search database. The HCV receptor was modeled from HCV genotype3 house amino acids sequence by YASARA Structure software, and the minimized ligands catalytic triad at HIS-72, ASP-96, and 154 as reported previously. The docking of compound 4 to HCV protease was -28.1± 2.2 kcal/mol. The primary binding bonds were hydrogen bonds (2) and Van Der Waals (12). The ve site of HCV protease was through His-72 and Ser-
The results of our study have shown that compound 4 considerably inhibit HCV protease in test compounds. Therefore, further analysis was carried out based system using HCV replicon 13 assay. First, the toxic effect of compound 4 was identified by cell viability assay. The 50% 1 cytotoxic concentration (CC 50 ) of compound 4 was estimated to be >80 µM for 24, 48 and 2 72 h time points that showed approximately 80% of cell viability as determined by MTT 3 assay (Fig. 5A ). Besides that, compound 4 also showed dose-dependent inhibition of HCV 4 replication with a considerable reduction in Rluc activity at 40 µM (p<0.01, Two way 5 ANOVA). However, the results showed insignificant effects for the time points on the 6 compound activity (p>0.05, Two way ANOVA) as described in figure 5B . Besides, to confirm 7 the results from HCV replicon assay, further analysis with immunostaining was applied. 8 Immunostaining against HCV NS3 viral protein has shown that the levels of NS3 viral protein 9 decreased in a dose-dependent manner after treatment with compound 4. (Fig. 6 ). Cell viability after the treatment with compound 4 was analyzed at 24, 48, and 72 h using nonradioactive cell proliferation assay. The 50% cytotoxic concentration (CC50) of compound 4 was more than 80 µM. (B) Huh-7 cells harboring HCV replicon were seeded well plate and treated with compound 4 (DMSO, 10, 20, 40, and 80 µM). After 24, 48 and 72 h of incubation, the luminescence signal of the Rluc was measured with a Renilla luciferase assay kit. The lowest concentration of the compound that showed significant (p<0.01) reduction in the activity of the Rluc reporter was 40 µM. Two-way ANOVA with the test was utilized.
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HCV activity of compound 4 using HCV replicon assay. (A)
Cell viability after the treatment with compound 4 was analyzed at 24, 48, and 72 h using (CC50) of 7 cells harboring HCV replicon were seeded well plate and treated with compound 4 (DMSO, 10, 20, 40, and 80 µM). After 24, asured with a Renilla luciferase assay kit. The lowest concentration of the compound that showed significant way ANOVA with the ]. This study showed that the toxic dose of compound 4 was more than 80 µM for 24, 48, 18 and 72 h. 19 Interestingly, compound 4 showed dose-dependent inhibition against HCV replication with a 20 considerable reduction in Rluc activity at 40 µM. The Rluc activity was relative to the viral 21 RNA replication in HCV replicon assay in HCV replicon-containing Huh-7 cells. This finding 22 was further investigated in this study by immunostaining technique that showed the 23 inhibitory effects of compound 4 against HCV NS3-4Apro were dependent on increasing 1 concentrations of the compound. 2 In conclusion, this study has identified a unique small molecule lead to developing for HCV 
